Radius Health

231 articles with Radius Health

• Radius Health Divests RAD 140 Program to Ellipses Pharma

  10/1/2020

  Radius Health, Inc. announced that the company has successfully sold its second oncology pipeline asset – RAD 140 - to Ellipses Pharma Limited, completing Radius’s divestment of its oncology assets.

• Radius Health Provides Business Update - Sep 24, 2020

  9/24/2020

  Radius Health, Inc., announced that Jose Carmona will be stepping down as Chief Financial Officer of Radius Health, Inc., with immediate effect.

• Radius Health & Menarini Group Provide Elacestrant Update

  9/24/2020

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) and the Menarini Group today announced an update on the elacestrant Phase 3 EMERALD trial.

• Radius Health Announces Scientific Presentations on abaloparatide at ASBMR 2020 Annual MeetingIncludes detailed results from Phase 2 histomorphometry study and Teijin’s Phase 3 trial in Japan

  9/9/2020

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced data presentations on abaloparatide-SC at the upcoming American Society for Bone and Mineral Research (ASBMR) 2020 Annual Virtual Meeting which will take place between September 11-15.  “We are excited that data from our histomorphometry study, showing that treatment with abaloparatide results in significant increase in bone formation in postmenopausal women with

• Radius Health: Enrollment Completed for Phase 3 wearABLe trial

  9/8/2020

  The study was designed to look at the effects on bone mineral density of abaloparatide delivered via a novel transdermal device compared with the current subcutaneous formulation, marketed as TYMLOS®.

• Radius Health to Participate in the Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley Virtual 18th Annual Global Healthcare Conference

  9/2/2020

  A live webcast of the fireside presentation will be available by visiting the Investors section of the Company’s website at https://ir.radiuspharm.com/events-and-presentations.

• Radius Health Provides Business Update

  8/25/2020

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced a business update including the extension of the patent for TYMLOS® as well as the completion of enrollment for its Phase 3 study, which is assessing the safety and efficacy of abaloparatide-SC in men with osteoporosis.

• Sean Murphy joins Radius Health Board of Directors

  8/10/2020

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate effect.

• Radius Health Announces Second Quarter 2020 Operating Results

  8/10/2020

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the second quarter ended June 30, 2020 and provided a business update.

• Radius Health to Announce Second Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Monday, August 10, 2020

  7/27/2020

  Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Monday, August 10, 2020

• Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant

  7/23/2020

  Menarini licenses global development and commercialization rights of elacestrant, an oral SERD currently in late stage Phase 3 development

• Pivotal Phase III trial of abaloparatide-SC in Japanese women and men with osteoporosis achieves primary endpoint

  5/27/2020

  Radius partner Teijin Pharma has submitted a New Drug Application for abaloparatide-SC for treatment of osteoporosis in Japan

• Radius Health Announces First Quarter 2020 Operating Results

  5/7/2020

  TYMLOS® U.S. net sales of $48 million, with 61% year over year growth Our three Phase 3 studies continue to advance amid slowdown in recruitment due to COVID-19 pandemic. Anticipated data read-outs remain on track for second half of 2021 Due to anticipated impact of pandemic, 2020 TYMLOS U.S. net revenue guidance mid-point reduced by 10% to between $190M and $220M. Full year cash burn is expected to be below $100M Kelly Martin appointed President and Chief Executive Officer as of Apr

• Radius Health Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  4/28/2020

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Company’s Board of Directors (the “Board”) granted G. Kelly Martin, in connection with his appointment as Chief Executive Officer and President of the Company,

• Radius Health Announces CEO Leadership Transition

  4/28/2020

  Radius Health, Inc., announced that Jesper Hoeiland will step down as President and Chief Executive Officer to return, after many years abroad, to his home country of Denmark.

• Radius Health to Present at Cowen 40th Annual Healthcare Conference

  3/3/2020

  Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President & CEO and Pepe Carmona, CFO will present a corporate update at the Cowen 40th Annual Healthcare Conference in Boston at 08:40 a.m. ET on Wednesday, March 4, 2020.

• Radius Health Announces Fourth Quarter and Full-Year 2019 Operating Results

  2/27/2020

  TYMLOS ® U.S. net sales grew to $56 million in the fourth quarter of 2019,  totaling $173M for full-year 2019, exceeding the Company’s guidance of $168 to 172M TYMLOS exited 2019 with majority share in new patients 1 , on track for market leadership in 2020 2020 TYMLOS U.S. net revenue expected to be between $220 and $235M and  full-year cash burn expected to be below $80M Recruitment of three Phase 3 studies is advancing and expected to be completed in 2020, with anticipate

• Radius Health to Present at 9th Annual SVB Leerink Partners Global Healthcare Conference

  2/13/2020

  Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President & CEO and Pepe Carmona, CFO will present a corporate update at the 9th Annual SVB Leerink Partners Global Healthcare Conference at 10:30 a.m. ET on Thursday, February 27, 2020.

• Radius Health to Announce Fourth Quarter and Full Year 2019 Financial Results, Host Conference Call and Live Webcast on Thursday, February 27, 2020

  2/13/2020

  Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter and full year 2019 financial results on Thursday, February 27, 2020.

• Radius Exceeds 2019 Financial Guidance and Provides Business Update at the 38th Annual J.P. Morgan Healthcare Conference

  1/13/2020

  Full-Year 2019 TYMLOS U.S. net revenue exceeds financial guidance, surpassing $172M.1, on track for market leadership in 2020.